Growth factors and trefoil peptides in gastrointestinal health and disease.

[1]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[2]  R. Playford,et al.  Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis , 2004, Peptides.

[3]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[4]  Richard O'Kennedy,et al.  Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Ellis,et al.  Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Zink,et al.  Hepatocyte growth factor induces Mcl‐1 in primary human hepatocytes and inhibits CD95‐mediated apoptosis via Akt , 2004, Hepatology.

[8]  D. Chung,et al.  Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer , 2004, Cancer Research.

[9]  Neil A. Reynolds,et al.  Cetuximab: in the treatment of metastatic colorectal cancer. , 2004, Drugs.

[10]  S. Bernasconi,et al.  Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. , 2003, The Journal of endocrinology.

[11]  Dean P. Jones,et al.  Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. , 2003, Annual review of nutrition.

[12]  D. Coppola,et al.  Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. , 2003, Cancer research.

[13]  F. Schildberg,et al.  Reduced Survival of Rectal Cancer Patients With Increased Tumor Epidermal Growth Factor Receptor Levels , 2003, Diseases of the colon and rectum.

[14]  D. W. Fry,et al.  CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. , 2003, Seminars in oncology.

[15]  I Duluc,et al.  The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development , 2003, Gut.

[16]  M. Abaza,et al.  Antisense Oligodeoxynucleotide Directed against c-myb Has Anticancer Activity and Potentiates the Antiproliferative Effect of Conventional Anticancer Drugs Acting by Different Mechanisms in Human Colorectal Cancer Cells , 2003, Tumor Biology.

[17]  E. K. Maloney,et al.  An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. , 2003, Cancer research.

[18]  H. Cho,et al.  Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. , 2003, The Journal of nutrition.

[19]  Domenico Coppola,et al.  Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.

[20]  R. Playford,et al.  Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. , 2003, The New England journal of medicine.

[21]  M. Mareel,et al.  Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells , 2003, Oncogene.

[22]  A. Bedirli,et al.  Role of Granulocyte-Macrophage Colony-Stimulating Factor on Apoptosis Induced by Ischemia-Reperfusion in the Intestinal Epithelium , 2003, European Surgical Research.

[23]  Robert N. Taylor,et al.  beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. , 2003, Cancer research.

[24]  B. Sands,et al.  Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial , 2003, Alimentary pharmacology & therapeutics.

[25]  Hua Yang,et al.  Keratinocyte growth factor improves epithelial function after massive small bowel resection , 2003 .

[26]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[27]  R. Poulsom,et al.  A study of regional gut endoderm potency by analysis of Cdx2 null mutant chimaeric mice. , 2003, Developmental biology.

[28]  D. Coppola,et al.  Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. , 2003, Anticancer research.

[29]  G. Besner,et al.  Heparin-binding EGF-like growth factor downregulates expression of adhesion molecules and infiltration of inflammatory cells after intestinal ischemia/reperfusion injury. , 2003, Journal of pediatric surgery.

[30]  A. Khorana,et al.  Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma , 2003, Cancer.

[31]  N. Kapel,et al.  Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. , 2003, Gastroenterology.

[32]  M. Gillingham,et al.  IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[33]  Catherine S. Williams,et al.  Ileal Cytokine Dysregulation in Experimental Necrotizing Enterocolitis Is Reduced by Epidermal Growth Factor , 2003, Journal of pediatric gastroenterology and nutrition.

[34]  M. Ruge,et al.  Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[35]  R. Playford,et al.  Use of the ‘nutriceutical’, bovine colostrum, for the treatment of distal colitis: results from an initial study , 2002, Alimentary pharmacology & therapeutics.

[36]  R. Playford,et al.  Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. , 2002, The American journal of pathology.

[37]  H. Senn,et al.  Insulin-like growth factors and cancer. , 2002, The Lancet. Oncology.

[38]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[39]  J. Holst,et al.  Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. , 2001, Gastroenterology.

[40]  R. Playford,et al.  Epidermal growth factor reduces multiorgan failure induced by thioacetamide , 2001, Gut.

[41]  B. Warner,et al.  Epidermal growth factor is critical for intestinal adaptation following small bowel resection , 2000, Microscopy research and technique (Print).

[42]  S. Blum,et al.  Role of glutamine on the de novo purine nucleotide synthesis in Caco-2 cells , 2000, European journal of nutrition.

[43]  T. Ziegler,et al.  Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. , 2000, Veterinary surgery : VS.

[44]  J. Thompson,et al.  Epidermal growth factor and the short bowel syndrome. , 1999, JPEN. Journal of parenteral and enteral nutrition.

[45]  R. Playford,et al.  Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Brenner,et al.  L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. , 1997, The American journal of physiology.

[47]  R. Playford.  Trefoil Peptides: What Are They and What Do They Do? , 1997, Journal of the Royal College of Physicians of London.

[48]  R. Playford,et al.  Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. , 1995, Gastroenterology.

[49]  V. Gorgoulis,et al.  Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas1 , 1993 .

[50]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.